<DOC>
	<DOCNO>NCT00252798</DOCNO>
	<brief_summary>The primary objective trial determine Maximum tolerate dose , , combination daily ZD1839 250 mg carboplatin AUC 2 60 Gray ( Gy ) irradiation 45 mg/m2 paclitaxel .</brief_summary>
	<brief_title>ZD1839 ( Iressaâ„¢ ) Concurrent Chemo-Radiation Patients With Locally Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients histologically cytologically confirm locally advanced stage IIIA IIIB NSCLC ( without pleural effusion ) Patients apical tumour supraclavicular node acceptable easily encompass one radiation field Minimum life expectancy treatment 6 month WHO performance status 01 Patients previous malignancy NSCLC Previous radiotherapy NSCLC Previous immunotherapy chemotherapy Any unresolved chronic toxicity great CTC grade 2 previous anticancer therapy Forced expiratory volume 1 second ( FEV1 ) less 1 litre ( L ) Absolute neutrophil count ( ANC ) less 1.5 x 109/L platelet less 100 x 109/L Serum bilirubin great 1.25 time upper limit reference range ALT AST great 2.5 time ULRR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
</DOC>